Guazzi M D, Cipolla C, Sganzerla P, Agostoni P G, Fabbiocchi F, Pepi M
Eur Heart J. 1983 Jan;4 Suppl A:181-7. doi: 10.1093/eurheartj/4.suppl_a.181.
Calcium channel blockers relax the arterial smooth vasculature and lower blood pressure when it is elevated because of excessive vasoconstriction. They may be regarded as ventricular unloading agents. Nifedipine (11 cases, Group 1) and verapamil (12 cases, Group 2) were tested in hypertensive patients with cardiac enlargement (LV diastolic diameter greater than or equal to 60 mm), ECG signs of LV strain, lung congestion and dyspnea at rest, in an acute (nifedipine 20 mg; verapamil 160 mg) and 1-month (nifedipine 20 mg q.i.d.; verapamil 160 mg t.i.d.) therapeutic evaluation. In the acute study nifedipine reduced systemic vascular resistance (SVR), mean arterial pressure (MAP), mean pulmonary wedge pressure (PWP) and LV diastolic diameter (DD) and improved cardiac index (CI) and Vcf. In Group 2 verapamil reduced SVR and MAP, improved CI and was not effective on PWP, LV DD and Vcf. Verapamil was discontinued in 2 patients who developed severe dyspnea at rest after 3-4 days of continued oral treatment. At the end of the trial Vcf, PWP and LV DD were unchanged in the remaining subjects in Group 2 despite persistent pressure reduction. In Group 1 all of the patients had relief of dyspnea and lung congestion, reduction of heart size, persistent decrease of MAP and PWP, and improvement in Vcf. The only side effect was ankle edema in 4 cases. A less potent vasodilating action of verapamil and a predominant depression in cardiac contractility may account for the different results with the two drugs, in spite of a shared antihypertensive effect. These findings prove that functional changes in the failing hypertensive heart may differ after nifedipine compared to verapamil as a result of interaction and relative preponderance of influences on afterload and contractility.
钙通道阻滞剂可使动脉平滑肌血管舒张,在因血管过度收缩导致血压升高时降低血压。它们可被视为心室减负药物。对患有心脏扩大(左心室舒张直径大于或等于60毫米)、左心室劳损的心电图征象、肺充血以及静息时呼吸困难的高血压患者,进行了硝苯地平(11例,第1组)和维拉帕米(12例,第2组)的急性(硝苯地平20毫克;维拉帕米160毫克)和为期1个月(硝苯地平20毫克,每日4次;维拉帕米160毫克,每日3次)治疗评估。在急性研究中,硝苯地平降低了全身血管阻力(SVR)、平均动脉压(MAP)、平均肺楔压(PWP)和左心室舒张直径(DD),并改善了心脏指数(CI)和心室周径缩短率(Vcf)。在第2组中,维拉帕米降低了SVR和MAP,改善了CI,但对PWP、左心室DD和Vcf无效。2例患者在持续口服治疗3 - 4天后出现严重静息呼吸困难,停用了维拉帕米。在试验结束时,尽管血压持续降低,但第2组其余受试者的Vcf、PWP和左心室DD均未改变。在第1组中,所有患者的呼吸困难和肺充血均得到缓解,心脏大小减小,MAP和PWP持续下降,Vcf得到改善。唯一的副作用是4例出现踝关节水肿。尽管两种药物都有降压作用,但维拉帕米的血管舒张作用较弱且对心脏收缩力有明显抑制,这可能是两种药物产生不同结果的原因。这些发现证明,由于对后负荷和收缩力的相互作用及相对优势影响不同,硝苯地平和维拉帕米作用于衰竭的高血压心脏后,其功能变化可能有所不同。